

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PFIZER, INC.,
Petitioner,

v.

GENENTECH, INC.,
Patent Owner.

Case IPR2017-01488
Patent 6,407,213 B2

PETITIONER'S FIRST AMENDED APPENDIX OF EXHIBITS

PETITIONER'S EXHIBIT LIST	
Exhibit No.	Description
1001	U.S. Patent No. 6,407,213, <i>Method for making humanized antibodies</i> (filed July 17, 1993) (issued June 18, 2002)
1002 Vols. 1–10	File History for U.S. Patent No. 6,407,213
1003	Declaration of Dr. Foote in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213
1003A	<i>Curriculum Vitae</i> of Dr. Foote
1003B	Materials Reviewed by Dr. Foote
1003C–Q	Exhibits C–Q of Dr. Foote's Declaration
1004	Declaration of Mr. Buss in Support of Petition for <i>Inter Partes</i> Review of Patent No. 6,407,213
1004A	<i>Curriculum Vitae</i> of Mr. Buss
1004B	Materials Reviewed by Mr. Buss
1005	Reserved
1006	Reserved
1007	Reserved
1008	Reserved
1009	Reserved
1010	Reserved
1011	Reserved
1012	Reserved
1013	Reserved
1014	Reserved
1015	Reserved
1016	Reserved
1017	Reserved
1018	Reserved
1019	Reserved
1020	Reserved

PETITIONER'S EXHIBIT LIST	
Exhibit No.	Description
1021	Hudziak <i>et al.</i> , <i>p185^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor</i> , 9(3) MOLECULAR CELLULAR BIOLOGY 1165–72 (1989) (“Hudziak”)
1022	Köhler <i>et al.</i> , <i>Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity</i> , 256(5517) NATURE 495–97 (1975)
1023	Prabakaran, <i>The Quest for a Magic Bullet</i> , 349(6246) SCIENCE 389 (2015)
1024	Marks, <i>The Story of Cesar Milstein and Monoclonal Antibodies: A Healthcare Revolution in the Making</i> , http://www.whatisbiotechnology.org/exhibitions/milstein (last accessed March 23, 2017)
1025	Cosimi <i>et al.</i> , <i>Treatment of Acute Renal Allograft Rejection with OKT3 Monoclonal Antibody</i> , 32(6) TRANSPLANTATION 535–39 (1981) (“Cosimi ‘81”)
1026	Ortho Multicenter Transplant Study Group, <i>A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants</i> , 313(6) NEW ENG. J. MED. 337–42 (1985) (“OMTSG ‘85”)
1027	Jaffers <i>et al.</i> , <i>Monoclonal Antibody Therapy: Anti-Idiotypic and Non-Anti-Idiotypic Antibodies to OKT3 Arising Despite Intense Immunosuppression</i> , 41(5) TRANSPLANTATION 572–78 (1986) (“Jaffers ‘86”)
1028	Sears <i>et al.</i> , <i>Phase-I Clinical Trial of Monoclonal Antibody in Treatment of Gastrointestinal Tumours</i> , 1 LANCET 762–65 (1982)
1029	Sikora, <i>Monoclonal Antibodies in Oncology</i> , 35(4) J. CLINICAL PATHOLOGY 369–75 (1982)
1030	<i>Protein Data Bank - Chronology</i> , National Science Foundation, https://www.nsf.gov/news/news_summ.jsp?cntn_id=100689 (last accessed April 12, 2017)

PETITIONER'S EXHIBIT LIST	
Exhibit No.	Description
1031	Morrison <i>et al.</i> , <i>Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains With Human Constant Region Domains</i> , 81(21) PROC. NAT'L ACAD. SCI. USA 6851–55 (1984) (“Morrison ‘84”)
1032	Liu <i>et al.</i> , <i>Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis of Cancer Cells</i> , 84(10) PROC. NAT'L ACAD. SCI. USA 3439–43 (1987) (“Liu ‘87”)
1033	Jones <i>et al.</i> , <i>Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse</i> , 321(6069) NATURE 522–25 (1986) (“Jones ‘86”)
1034	Queen <i>et al.</i> , <i>A Humanized Antibody That Binds to the Interleukin 2 Receptor</i> , 86(24) PROC. NAT'L ACAD. SCI. USA 10029–33 (1989) (“Queen 1989”)
1035	Kirkman <i>et al.</i> , <i>Early Experience with Anti-Tac in Clinical Renal Transplantation</i> , 21(1) TRANSPLANTATION PROC. 1766–68 (1989) (“Kirkman ‘89”)
1036	Waldmann <i>et al.</i> , <i>The Interleukin-2 Receptor: A Target for Monoclonal Antibody Treatment of Human T-Cell Lymphotropic Virus I-Induced Adult T-Cell Leukemia</i> , 82(6) BLOOD 1701–12 (1993) (“Waldman ‘93”)
1037	Hakimi <i>et al.</i> , <i>Reduced Immunogenicity and Improved Pharmacokinetics of Humanized ANTI-Tac in Cynomolgus Monkeys</i> , 147(4) J. IMMUNOLOGY 1352–59 (1991) (“Hakimi ‘91”)
1038	Vincenti <i>et al.</i> , <i>Interleukin 2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation</i> , 338(3) NEW ENG. J. MED. 161–65 (1998) (“Vincenti ‘98”)
1039	<i>SEER Stat Fact Sheets: Breast Cancer</i> , National Cancer Institute, http://seer.cancer.gov/statfacts/html/breast.html (last accessed March 17, 2017)
1040	Harris <i>et al.</i> , <i>Medical Progress: Breast Cancer</i> , 327(5) NEW ENG. J. MED. 319–28 (1992) (“Harris ‘92”)
1041	King <i>et al.</i> , <i>Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma</i> , 229(4717) SCIENCE 974–76 (1985) (“King ‘85”)

PETITIONER'S EXHIBIT LIST	
Exhibit No.	Description
1042	Semba <i>et al.</i> , <i>A v-erbB-Related Protooncogene, c-erbB-2, is Distinct from the c-erbB-1 / Epidermal Growth Factor-Receptor Gene and is Amplified in a Human Salivary Gland Adenocarcinoma</i> , 82(19) PROC. NAT'L ACAD. SCI. USA 6497-01 (1985) ("Semba '85")
1043	Coussens <i>et al.</i> , <i>Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene</i> , 230(4730) SCIENCE 1132-39 (1985) ("Coussens '85")
1044	Fukushige <i>et al.</i> , <i>Localization of a Novel v-erbB-Related Gene, c-erbB-2, on Human Chromosome 17 and its Amplification in a Gastric Cancer Cell Line</i> , 6(3) MOLECULAR CELLULAR BIOLOGY 955-58 (1986)
1045	Slamon <i>et al.</i> , <i>Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene</i> , 235(4785) SCIENCE 177-82 (1987) ("Slamon '87")
1046	Kraus <i>et al.</i> , <i>Overexpression of the EGF Receptor-Related Proto-Oncogene erbB-2 in Human Mammary Tumor Cell Lines by Different Molecular Mechanisms</i> , 6(3) The EMBO J. 605- 10 (1987)
1047	Hudziak <i>et al.</i> , <i>Increased Expression of the Putative Growth Factor Receptor p185^{HER2} Causes Transformation and Tumorigenesis of NIH 3T3 Cells.</i> , 84(20) PROC. NAT'L ACAD. SCI. USA 7159-163 (1987) ("Hudziak '87")
1048	Shepard <i>et al.</i> , <i>Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic</i> , 11(3) J. CLINICAL IMMUNOLOGY, 117-27 (1991)
1049	Chothia <i>et al.</i> , <i>Conformations of Immunoglobulin Hypervariable Regions</i> , 342(21) NATURE 877-83 (1989) ("Chothia '89")
1050	Queen, International Publication No. WO 1990/07861 (published July 26, 1990) ("Queen 1990")

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.